Testosterone as a predictor of pathological stage in clinically localized prostate cancer.
about
Testosterone for the aging male; current evidence and recommended practicePreoperative glycemic control status as a significant predictor of biochemical recurrence in prostate cancer patients after radical prostatectomyLow pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancerSerum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.Endogenous and exogenous testosterone and prostate cancer: decreased-, increased- or null-risk?Glycemic control and prostate cancer progression: results from the SEARCH database.Testosterone deficiency and replacement: Myths and realities.Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients.Higher body mass index increases the risk for biopsy-mediated detection of prostate cancer in Chinese men.Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis.A rational approach to androgen therapy for hypogonadal men with prostate cancer.Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.Targeting the stromal androgen receptor in primary prostate tumors at earlier stages.Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer.The role of testosterone in the pathogenesis of prostate cancer.Testosterone therapy and prostate cancer.Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels.Low levels of serum testosterone in middle-aged men impact pathological features of prostate cancer.Androgen regulation of prostate cancer: where are we now?Differing levels of testosterone and the prostate: a physiological interplay.Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients.The safety of testosterone supplementation therapy in prostate cancer.Low Testosterone Alters the Activity of Mouse Prostate Stem Cells.Circulating steroid hormones in prostate carcinogenesis. Part 1 - Androgens.Testosterone Therapy Among Prostate Cancer Survivors.Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.Testosterone augments polyphenol-induced DNA damage response in prostate cancer cell line, LNCaP.Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer.Effects of glycyrrhetinic acid and liquorice extract on cell proliferation and prostate-specific antigen secretion in LNCaP prostate cancer cells.Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy.Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial.The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.Changes in sex hormone levels after radical prostatectomy: Results of a longitudinal cohort study.Serum levels of hypothalamic-pituitary-testicular axis hormones in men with or without prostate cancer or atypical small acinar proliferation.Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.Metabolic syndrome and urologic diseases.Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer.
P2860
Q24647679-5BD22DED-E014-4485-8AFA-988A33B82D1EQ28546623-2C2F8FB9-7BB2-4491-B4FC-A11CF6B4E26FQ30565173-AD04CBD3-C42B-4432-B2CB-CC7DA6F33E2EQ33599365-C690CFA0-6881-4252-BD25-5F74622028FAQ33764496-0B48F421-2AA5-4E3F-A347-9E6263CF999DQ33890197-41B24AA3-A1B9-4C54-8998-5F2A07AF5993Q34091905-2E02601F-5A40-4A22-BF87-8F2804E00D61Q34093530-5AF8CF0E-EC88-401C-8833-D0A80F356D4EQ34128835-A3DED48C-F933-49A9-8715-2A2B31D713B2Q35599285-EA19CDD9-5C25-4AAE-8690-5C2B4120F685Q36255272-C05D65F9-306A-4A37-A2E6-1A4F4C511D25Q36278639-4E043CA0-6057-4113-91FE-A48FB91AB3E1Q36381291-B7B0C994-B2D1-4C47-93BB-67D3FE62C47AQ36858449-51C91776-3DC4-4FE7-8583-503C4CC054BCQ36875803-40F340AF-E8A9-4EE6-B66B-48277AC5CC20Q37145218-DF9D084A-5996-4229-923E-35E0F4920F70Q37531045-C01CEB32-D945-43A1-BDAA-D74CA4DD8D3FQ37605856-BD50FECE-37F6-4843-94FA-EF8898DCA48CQ37710930-B1002B7C-F050-4B67-BB8E-9E8593FC6B4DQ37836264-4B6D4B76-7131-4377-BEA2-4F9D3AE64BBAQ37883014-8F9431D6-C98A-4C43-803A-5C55412445FBQ38175843-B15B4715-19FC-4EF3-A068-BF04FDA8DBDBQ38234728-8C853042-ADBF-4644-95CC-FB232962EFC4Q38439120-49114F3A-9D7B-4115-BFAF-243B3548B338Q38471454-6D48DDE6-BEF1-479B-8E37-7322153BD301Q38913362-991A539F-160D-44EB-89E8-FCE78F13C124Q39123647-8D5F1279-BDAD-4104-9C9C-BEF32C4D0258Q39623453-5F54E89F-2278-477B-9ED7-AF61A70DA7B7Q39957624-AF1D17E6-EF08-4ECE-A4BC-C21299823F23Q39991386-8C6FA8F5-0364-42F0-A2A3-C498FF93C5B6Q40165950-B9788725-1676-4E30-A7FA-CF2AF85AFE83Q40463189-9101191B-05F9-42E1-8F94-4C089BCA414FQ40485378-2229B32A-3072-4200-89DF-819FC2B74E07Q40501272-19B6728B-8140-4D16-B966-AF4A0BDF8568Q41054535-5C55E5D6-EF2B-419F-9F96-6D3566411509Q42058586-8CDE90A3-C045-48B7-9AC6-CF102406A3AFQ42133690-1C5A3B20-D948-4034-BA8B-45207650D6D0Q42617082-FD83F809-C20F-47C3-B191-066767B682E8Q42757693-E9A7F675-128F-4F32-98B5-3CE38D0FFC2AQ42926024-CFD4CCFA-2451-42E8-83EE-6A2EC615FCF5
P2860
Testosterone as a predictor of pathological stage in clinically localized prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Testosterone as a predictor of ...... lly localized prostate cancer.
@ast
Testosterone as a predictor of ...... lly localized prostate cancer.
@en
type
label
Testosterone as a predictor of ...... lly localized prostate cancer.
@ast
Testosterone as a predictor of ...... lly localized prostate cancer.
@en
prefLabel
Testosterone as a predictor of ...... lly localized prostate cancer.
@ast
Testosterone as a predictor of ...... lly localized prostate cancer.
@en
P2093
P2860
P1476
Testosterone as a predictor of ...... lly localized prostate cancer.
@en
P2093
Fernando J Bianco
Ginger Isom-Batz
James A Eastham
John P Mulhall
Michael W Kattan
P2860
P304
P356
10.1097/01.JU.0000158040.33531.E7
P407
P50
P577
2005-06-01T00:00:00Z